PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Wang, Leiping ^a   Zhang, Qunling ^a   Zhang, Jian ^a   Sun, Si ^a   Guo, Haiyi ^a   Jia, Zhen ^a   Wang, Biyun ^a   Shao, Zhimin ^a   Wang, Zhonghua ^a   Hu, Xichun ^a  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; BEVACIZUMAB; CAPECITABINE; CISPLATIN; DNA; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEMCITABINE; LAPATINIB; NAVELBINE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; TAXANE DERIVATIVE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; DEOXYCYTIDINE; DRUG DERIVATIVE; FLUOROURACIL; MONOCLONAL ANTIBODY; PIK3CA PROTEIN, HUMAN; PTEN PROTEIN, HUMAN; QUINAZOLINE DERIVATIVE; TAXOID; TRASTUZUMAB; TUMOR PROTEIN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER MORTALITY; CANCER RESISTANCE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SENSITIVITY; DRUG TOLERABILITY; GENE MUTATION; HIGH RISK POPULATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFORMED CONSENT; MAJOR CLINICAL STUDY; METASTATIC BREAST CANCER; OUTCOME ASSESSMENT; POLYMERASE CHAIN REACTION; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SIGNAL TRANSDUCTION; SURVIVAL TIME; TRANSLATIONAL RESEARCH; TREATMENT RESPONSE; BREAST TUMOR; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG RESISTANCE; ENZYME ACTIVATION; ENZYMOLOGY; EXON; FEMALE; FOLLOW UP; GENETICS; MIDDLE AGED; MUTATION; NUCLEOTIDE SEQUENCE; PHYSIOLOGY; PROTO ONCOGENE; TREATMENT OUTCOME;

ADULT; AGED; ANTHRACYCLINES; ANTIBIOTICS, ANTINEOPLASTIC; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; EXONS; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; GENES, ERBB-2; HUMANS; MIDDLE AGED; MUTATION; NEOPLASM PROTEINS; PHOSPHATIDYLINOSITOL 3-KINASES; PTEN PHOSPHOHYDROLASE; QUINAZOLINES; TAXOIDS; TREATMENT OUTCOME;

EID: 79958765919     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-248     Document Type: Article

References (57)

1. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001, 344(11):783-792. 10.1056/NEJM200103153441101, 11248153.
2. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005, 353(16):1673-1684. 10.1056/NEJMoa052122, 16236738.
3. Van Pelt AE, Mohsin S, Elledge RM, Hilsenbeck SG, Gutierrez MC, Lucci A, Kalidas M, Granchi T, Scott BG, Allred DC. Neoadjuvant trastuzumab and docetaxel in breast cancer: preliminary results. Clin Breast Cancer 2003, 4(5):348-353. 10.3816/CBC.2003.n.040, 14715110.
4. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002, 20(3):719-726. 10.1200/JCO.20.3.719, 11821453.
5. She QB, Chandarlapaty S, Ye Q, Lobo J, Haskell KM, Leander KR, DeFeo-Jones D, Huber HE, Rosen N. Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling. PLoS One 2008, 3(8):e3065.. 2516933, 18725974.
6. Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, Sahin AA, Klos KS, Li P, Monia BP, Nguyen NT. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004, 6(2):117-127. 10.1016/j.ccr.2004.06.022, 15324695.
7. Berns K, Horlings HM, Hennessy BT, Madiredjo M, Hijmans EM, Beelen K, Linn SC, Gonzalez-Angulo AM, Stemke-Hale K, Hauptmann M. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 2007, 12(4):395-402. 10.1016/j.ccr.2007.08.030, 17936563.
8. Fujita T, Doihara H, Kawasaki K, Takabatake D, Takahashi H, Washio K, Tsukuda K, Ogasawara Y, Shimizu N. PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer. Br J Cancer 2006, 94(2):247-252. 10.1038/sj.bjc.6602926, 2361109, 16404430.
9. Fabi A, Metro G, Di Benedetto A, Nisticò C, Vici P, Melucci E, Antoniani B, Perracchio L, Sperduti I, Milella M. Clinical significance of PTEN and p-Akt co-expression in HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies. Oncology 2010, 78(2):141-149. 10.1159/000312656, 20389136.
10. Pandolfi PP. Breast cancer--loss of PTEN predicts resistance to treatment. N Engl J Med 2004, 351(22):2337-2338. 10.1056/NEJMcibr043143, 15564551.
11. Kataoka Y, Mukohara T, Shimada H, Saijo N, Hirai M, Minami H. Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines. Ann Oncol 2010, 21(2):255-62. 10.1093/annonc/mdp304, 19633047.
12. Bader AG, Kang S, Zhao L, Vogt PK. Oncogenic PI3K deregulates transcription and translation. Nat Rev Cancer 2005, 5(12):921-929. 10.1038/nrc1753, 16341083.
13. Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 2006, 7(8):606-619. 10.1038/nrg1879, 16847462.
14. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis C, Rodgers L, McCombie R. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997, 275(5308):1943-1947. 10.1126/science.275.5308.1943, 9072974.
15. Di Cristofano A, Pandolfi PP. The multiple roles of PTEN in tumor suppression. Cell 2000, 100(4):387-390. 10.1016/S0092-8674(00)80674-1, 10693755.
16. Brugge J, Hung MC, Mills GB. A new mutational AKTivation in the PI3K pathway. Cancer Cell 2007, 12(2):104-107. 10.1016/j.ccr.2007.07.014, 17692802.
17. Coughlin CM, Johnston DS, Strahs A, Burczynski ME, Bacus S, Hill J, Feingold JM, Zacharchuk C, Berkenblit A. Approaches and limitations of phosphatidylinositol-3-kinase pathway activation status as a predictive biomarker in the clinical development of targeted therapy. Breast Cancer Res Treat 2010, 124(1):1-11. 10.1007/s10549-010-1108-4, 20803067.
18. Kataoka Y, Mukohara T, Shimada H, Saijo N, Hirai M, Minami H. Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines. Ann Oncol 2010, 21(2):255-262. 10.1093/annonc/mdp304, 19633047.
19. Moy B, Kirkpatrick P, Kar S, Goss P. Lapatinib. Nat Rev Drug Discov 2007, 6(6):431-432. 10.1038/nrd2332, 17633789.
20. Scaltriti M, Chandarlapaty S, Prudkin L, Aura C, Jimenez J, Angelini PD, Sánchez G, Guzman M, Parra JL, Ellis C. Clinical benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated p95HER2 receptor. Clin Cancer Res 2010, 16(9):2688-2695. 10.1158/1078-0432.CCR-09-3407, 20406840.
21. Mukohara T. Mechanisms of resistance to anti-human epidermal growth factor receptor 2 agents in breast cancer. Cancer Sci
22. Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, Jagiello-Gruszfeld A, Crown J, Chan A, Kaufman B. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006, 355(26):2733-2743. 10.1056/NEJMoa064320, 17192538.
23. Di Leo A, Gomez HL, Aziz Z, Zvirbule Z, Bines J, Arbushites MC, Guerrera SF, Koehler M, Oliva C, Stein SH. Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. J Clin Oncol 2008, 26(34):5544-5552. 10.1200/JCO.2008.16.2578, 2651098, 18955454.
24. Johnston S, Pippen J, Pivot X, Lichinitser M, Sadeghi S, Dieras V, Gomez HL, Romieu G, Manikhas A, Kennedy MJ. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 2009, 27(33):5538-5546. 10.1200/JCO.2009.23.3734, 19786658.
25. Xia W, Husain I, Liu L, Bacus S, Saini S, Spohn J, Pry K, Westlund R, Stein SH, Spector NL. Lapatinib antitumor activity is not dependent upon phosphatase and tensin homologue deleted on chromosome 10 in ErbB2-overexpressing breast cancers. Cancer Res 2007, 67(3):1170-1175. 10.1158/0008-5472.CAN-06-2101, 17283152.
26. Eichhorn PJ, Gili M, Scaltriti M, Serra V, Guzman M, Nijkamp W, Beijersbergen RL, Valero V, Seoane J, Bernards R. Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. Cancer Res 2008, 68(22):9221-9230. 10.1158/0008-5472.CAN-08-1740, 2587064, 19010894.
27. Johnston S, Trudeau M, Kaufman B, Boussen H, Blackwell K, LoRusso P, Lombardi DP, Ben Ahmed S, Citrin DL, DeSilvio ML. Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy. J Clin Oncol 2008, 26(7):1066-1072. 10.1200/JCO.2007.13.9949, 18212337.
28. Koninki K, Barok M, Tanner M, Staff S, Pitkanen J, Hemmila P, Ilvesaro J, Isola J. Multiple molecular mechanisms underlying trastuzumab and lapatinib resistance in JIMT-1 breast cancer cells. Cancer Lett 2010, 294(2):211-219. 10.1016/j.canlet.2010.02.002, 20193978.
29. O'Brien NA, Browne BC, Chow L, Wang Y, Ginther C, Arboleda J, Duffy MJ, Crown J, O'Donovan N, Slamon DJ. Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib. Mol Cancer Ther 2010, 9(6):1489-1502. 10.1158/1535-7163.MCT-09-1171, 20501798.
30. Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 2009, 9(8):550-562. 10.1038/nrc2664, 19629070.
31. Wu G, Xing M, Mambo E, Huang X, Liu J, Guo Z, Chatterjee A, Goldenberg D, Gollin SM, Sukumar S. Somatic mutation and gain of copy number of PIK3CA in human breast cancer. Breast Cancer Res 2005, 7(5):R609-616. 10.1186/bcr1262, 1242128, 16168105.
32. Adélaïde J, Finetti P, Bekhouche I, Repellini L, Geneix J, Sircoulomb F, Charafe-Jauffret E, Cervera N, Desplans J, Parzy D. Integrated profiling of basal and luminal breast cancers. Cancer Res 2007, 67(24):11565-11575. 10.1158/0008-5472.CAN-07-2536, 18089785.
33. Buttitta F, Felicioni L, Barassi F, Martella C, Paolizzi D, Fresu G, Salvatore S, Cuccurullo F, Mezzetti A, Campani D. PIK3CA mutation and histological type in breast carcinoma: high frequency of mutations in lobular carcinoma. J Pathol 2006, 208(3):350-355. 10.1002/path.1908, 16353168.
34. Campbell IG, Russell SE, Choong DY, Montgomery KG, Ciavarella ML, Hooi CS, Cristiano BE, Pearson RB, Phillips WA. Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res 2004, 64(21):7678-7681. 10.1158/0008-5472.CAN-04-2933, 15520168.
35. Li SY, Rong M, Grieu F, Iacopetta B. PIK3CA mutations in breast cancer are associated with poor outcome. Breast Cancer Res Treat 2006, 96(1):91-95. 10.1007/s10549-005-9048-0, 16317585.
36. Maruyama N, Miyoshi Y, Taguchi T, Tamaki Y, Monden M, Noguchi S. Clinicopathologic analysis of breast cancers with PIK3CA mutations in Japanese women. Clin Cancer Res 2007, 13(2 Pt 1):408-414.
37. Saal LH, Holm K, Maurer M, Memeo L, Su T, Wang X, Yu JS, Malmström PO, Mansukhani M, Enoksson J. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res 2005, 65(7):2554-2559. 10.1158/0008-5472-CAN-04-3913, 15805248.
38. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, Yan H, Gazdar A, Powell SM, Riggins GJ. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004, 304(5670):554.. 10.1126/science.1096502, 15016963.
39. Kalinsky K, Jacks LM, Heguy A, Patil S, Drobnjak M, Bhanot UK, Hedvat CV, Traina TA, Solit D, Gerald W. PIK3CA mutation associates with improved outcome in breast cancer. Clin Cancer Res 2009, 15(16):5049-5059. 10.1158/1078-0432.CCR-09-0632, 19671852.
40. Perez-Tenorio G, Alkhori L, Olsson B, Waltersson MA, Nordenskjold B, Rutqvist LE, Skoog L, Stal O. PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer. Clin Cancer Res 2007, 13(12):3577-3584. 10.1158/1078-0432.CCR-06-1609, 17575221.
41. Steck PA, Pershouse MA, Jasser SA, Yung WK, Lin H, Ligon AH, Langford LA, Baumgard ML, Hattier T, Davis T. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 1997, 15(4):356-362. 10.1038/ng0497-356, 9090379.
42. Khan S, Kumagai T, Vora J, Bose N, Sehgal I, Koeffler PH, Bose S. PTEN promoter is methylated in a proportion of invasive breast cancers. Int J Cancer 2004, 112(3):407-410. 10.1002/ijc.20447, 15382065.
43. Bose S, Crane A, Hibshoosh H, Mansukhani M, Sandweis L, Parsons R. Reduced expression of PTEN correlates with breast cancer progression. Hum Pathol 2002, 33(4):405-409. 10.1053/hupa.2002.124721, 12055674.
44. Tsutsui S, Inoue H, Yasuda K, Suzuki K, Higashi H, Era S, Mori M. Reduced expression of PTEN protein and its prognostic implications in invasive ductal carcinoma of the breast. Oncology 2005, 68(4-6):398-404. 10.1159/000086981, 16020969.
45. Lee JS, Kim HS, Kim YB, Lee MC, Park CS, Min KW. Reduced PTEN expression is associated with poor outcome and angiogenesis in invasive ductal carcinoma of the breast. Appl Immunohistochem Mol Morphol 2004, 12(3):205-210. 10.1097/00129039-200409000-00004, 15551732.
46. Torres J, Navarro S, Rogla I, Ripoll F, Lluch A, Garcia-Conde J, Llombart-Bosch A, Cervera J, Pulido R. Heterogeneous lack of expression of the tumour suppressor PTEN protein in human neoplastic tissues. Eur J Cancer 2001, 37(1):114-121. 10.1016/S0959-8049(00)00366-X, 11165138.
47. Konecny GE, Pegram MD, Venkatesan N, Finn R, Yang G, Rahmeh M, Untch M, Rusnak DW, Spehar G, Mullin RJ. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 2006, 66(3):1630-1639. 10.1158/0008-5472.CAN-05-1182, 16452222.
48. Cizkova M, Bouchalova K, Trojanec R, Dziechciarkova M, Vacher S, Radova L. Impact of PIK3CA, PTEN and RPS6 status on lapatinib treatment outcome in advanced-stage breast cancer patients. 2010, SABCS conference, abs. P2-09-30.
49. Campone M, Juin P, Andre F, Bachelot T. Resistance to HER2 inhibitors: Is addition better than substitution? Rationale for the hypothetical concept of drug sedimentation. Crit Rev Oncol Hematol
50. Brünner-Kubath C, Shabbir W, Saferding V, Wagner R, Singer CF, Valent P, Berger W, Marian B, Zielinski CC, Grusch M. The PI3 kinase/mTOR blocker NVP-BEZ235 overrides resistance against irreversible ErbB inhibitors in breast cancer cells. Breast Cancer Res Treat
51. O'Brien NA, Wilcox K, McDermott M, Crown J, O'Donovan N, Slamon DJ. The role of the PI3K/AKT, RAS/MAPK and novel signaling pathways in resistance to HER2-targeted therapy. 2010, SABCS conference, abs. P4-01-06.
52. Dave B, Migliaccio I, Gutierrez MC, Wu MF, Chamness GC, Wong H, Narasanna A, Chakrabarty A, Hilsenbeck SG, Huang J, Rimawi M, Schiff R, Arteaga C, Osborne CK, Chang JC. Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers. J Clin Oncol 2011, 29(2):166-73. 10.1200/JCO.2009.27.7814, 21135276.
53. Toi M, Iwata H, Fujiwara Y, Ito Y, Nakamura S, Tokuda Y, Taguchi T, Rai Y, Aogi K, Arai T, Watanabe J, Wakamatsu T, Katsura K, Ellis CE, Gagnon RC, Allen KE, Sasaki Y, Takashima S. Lapatinib monotherapy in patients with relapsed, advanced, or metastatic breast cancer: efficacy, safety, and biomarker results from Japanese patients phase II studies. Br J Cancer 2009, 101(10):1676-82. 10.1038/sj.bjc.6605343, 2778543, 19844234.
54. Barbareschi M, Buttitta F, Felicioni L, Cotrupi S, Barassi F, Del Grammastro M, Ferro A, Dalla Palma P, Galligioni E, Marchetti A. Different prognostic roles of mutations in the helical and kinase domains of the PIK3CA gene in breast carcinomas. Clin Cancer Res 2007, 13(20):6064-6069. 10.1158/1078-0432.CCR-07-0266, 17947469.
55. Dupont Jensen J, Laenkholm AV, Knoop A, Ewertz M, Bandaru R, Weihua L, Hackl W, Barrett JC, Gardner H. PIK3CA mutations may be discordant between primary and corresponding metastatic disease in Breast Cancer. Clin Cancer Res
56. Depowski PL, Rosenthal SI, Ross JS. Loss of expression of the PTEN gene protein product is associated with poor outcome in breast cancer. Mod Pathol 2001, 14(7):672-676. 10.1038/modpathol.3880371, 11454999.
57. Saal LH, Johansson P, Holm K, Gruvberger-Saal SK, She QB, Maurer M, Koujak S, Ferrando AA, Malmström P, Memeo L. Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. Proc Natl Acad Sci USA 2007, 104(18):7564-7569. 10.1073/pnas.0702507104, 1855070, 17452630.